Metraipolis › archive › dc_d37cb5ccc665

Efficacy and safety of immune checkpoint inhibitors combined with chemotherapy versus bevacizumab combined with chemotherapy in first-line treatment of driver… — Europe PMC PMID:42661717

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/42661717
DOI: 10.3389/fonc.2026.1898071
License (as archived): solo-consultazione
Archived: 2026-10-16T20:22:06.551Z
SHA-256 of the archived text: ddc1081a471c5f88b3b62ca0ed260e4265f823d7e28a52c7d630ec7579974ef0
Stable URL of this page: https://metraipolis.com/documento/dc_d37cb5ccc665

How to cite

Efficacy and safety of immune checkpoint inhibitors combined with chemotherapy versus bevacizumab combined with chemotherapy in first-line treatment of driver… — Europe PMC PMID:42661717 — Europe PMC (en), https://europepmc.org/article/MED/42661717 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_d37cb5ccc665 (Metraipolis archive dc_d37cb5ccc665, sha256 ddc1081a471c5f88b3b62ca0ed260e4265f823d7e28a52c7d630ec7579974ef0)

BibTeX

@misc{dcd37cb5ccc665,
  title = {Efficacy and safety of immune checkpoint inhibitors combined with chemotherapy versus bevacizumab combined with chemotherapy in first-line treatment of driver… — Europe PMC PMID:42661717},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42661717},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_d37cb5ccc665; sha256 ddc1081a471c5f88b3b62ca0ed260e4265f823d7e28a52c7d630ec7579974ef0},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42661717. Agents can read the archived copy with the MCP tool read_document.